SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors aggressively debate the upcoming announcement of the trial's 80th event, with bullish community members highlighting potential acquisition interest from major pharmaceutical companies while bears express skepticism regarding trial integrity and dilution risks. The conversation is heavily focused on the high short interest and the anticipation that positive topline results could trigger a significant market move.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community speculation as investors anticipate imminent Phase 3 VELA data, fueling intense M&A discussions and optimism that sonelokimab will emerge as a best-in-class treatment for hidradenitis suppurativa. The community is closely watching for a potential data release to coincide with upcoming investor presentations, which many believe could trigger a massive rerating event due to the drug's demonstrated efficacy and superior safety profile over existing competition.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which confirms that another major OEM has validated the company's solid-state battery technology after rigorous testing. The community is actively debating the significance of this partnership, weighing the long-term potential of the technology against frustrations over the lack of immediate commercial-scale revenue.

Roundhill ETF Trust - Roundhill Memory ETF

DRAM is seeing heavy investor interest driven by a perception that the memory sector has shifted from a cyclical trade to a structural AI infrastructure necessity, with strong sentiment tied to supply constraints in High Bandwidth Memory and anticipation for key earnings and IPO catalysts. The community is actively debating the durability of this demand cycle, with many bullish participants viewing recent pullbacks as buying opportunities while others monitor the volatility surrounding sector-wide re-ratings.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is experiencing intense investor interest as the community prepares for a series of pivotal Phase 3 clinical data readouts expected throughout the summer. While discussions are polarized between optimism for potential breakthroughs in mental health treatment and concerns regarding cash burn and dilution, the stock remains a central focus as investors weigh the high-reward upside of these upcoming trials against standard biotech risks.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors focus on its role in the AI-driven energy infrastructure sector, with community excitement fueled by the company's recent purchase orders from Frontier Power USA and ongoing developments in zinc-based long-duration energy storage. Bullish sentiment is heavily influenced by the belief that Eos provides a critical solution to power grid bottlenecks required by data centers, leading to active discussions regarding the stock's potential as a multi-year growth opportunity amidst increasing sector-wide demand for reliable, non-flammable energy storage.

Figma, Inc. is an AI-powered digital design and product development platform. The firm offers tools for teams to collaborate on the entire lifecycle of software creation. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing heavy volatility as investors debate the impact of AI on its software ecosystem, with community sentiment divided between concerns over profitability and high stock-based compensation versus the belief that institutional interest and upcoming product events will trigger a major reversal. Despite the price pressure, bullish investors are highlighting strong revenue growth and the potential for a short squeeze as key catalysts, while bears remain focused on valuation concerns and the competitive threat posed by emerging generative AI tools.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

Investors are intensely focused on the semiconductor sector as the iShares Semiconductor ETF (SOXX) reaches all-time highs, driven by extreme FOMO and aggressive institutional positioning in AI-related infrastructure. While bulls emphasize strong momentum and the indispensability of chips, many in the community are expressing skepticism, labeling the rally a bubble and warning that overvaluation, high debt, and potential geopolitical instability could lead to a significant reversal.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as market participants closely monitor geopolitical tensions in the Middle East and their potential impact on energy markets and interest rate sentiment. The community is actively debating the durability of the AI-driven tech rally amidst record market highs and ongoing economic uncertainty.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently trending due to intense community discussion surrounding its potential integration with space-tech giants and its upcoming June 24th webinar on neutral-atom quantum computing advancements. Investors are closely monitoring the stock's inclusion in the Russell 3000 index, balancing speculative enthusiasm for its quantum-sensing hardware and government contracts against concerns over market volatility and sector rotation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June 11, 2026, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new...

Savara Announces Chief Financial and Administrative Officer Transition

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Dave Lowrance, Chief Financial and Administrative Officer, is stepping down from his role for health-related reasons, effective July 15, 2026. As part of...

Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will host one-on-one meetings and participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on...

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reported new biomarker data from the...

Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The poster reports long-term efficacy and safety data...

Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, sponsored an oral presentation at the ATS 2026 International Conference that is taking place May 15-20, 2026, in Orlando, Florida. The presentation reported new exercise...

Savara Reports First Quarter Financial Results and Provides Business Update

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2026 and...

Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team will participate in a...

Savara (SVRA) to Release Earnings on Tuesday

Savara (NASDAQ:SVRA) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer

Oppenheimer started coverage on Savara in a report on Friday. They issued an "outperform" rating and a $11.00 price target for the company...

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

Savara Inc

SVRA Stock Slips Post-Market After FDA Delays Decision On Pulmonary Therapy

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$5.50
Prev Close	$5.38
Open	$5.51
Dividend Yield	0.00%
50-Day Moving Average	$5.26
Beta	1.11
Avg. Volume	1.28M
PE Ratio	-9.85

52-Week High	$7.01
52-Week Low	$1.98
Market Capitalization	$1.13B
EPS (Annual)	-$0.5344
Price to Book	6.40
Revenue Per Employee	$0.00

SVRASavara Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SVRA News